Look­ing to win back in­vestor con­fi­dence, Bio­Marin preps for its ‘largest launch’

Bio­Marin is ready to launch the first drug to treat achon­dropla­sia, the most com­mon form of dwarfism, in Vox­zo­go – it just needs an FDA green­light.

The US com­mer­cial team is plan­ning for Vox­zo­go’s launch at the end of the year with an “ex­pe­ri­enced” sales force al­ready in place, Bio­Marin ex­ecs told an­a­lysts in its quar­ter­ly call this week. The bio­phar­ma is al­so work­ing with the FDA on late-stage la­bel­ing and post-mar­ket­ing re­quire­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER